COVID-19 goes endemic: UK rides out omicron waves as immunity outpaces hospitalizations

By mid-2026, COVID-19 has clearly transitioned into an endemic phase marked by milder symptom profiles and shifting immunity dynamics. UK data reveals that common cold-like symptoms such as sore throat (62%), headache (53%), and runny nose (53%) dominate current infections, while severe symptoms like shortness of breath have dropped significantly to 16%, reducing hospitalizations and intensive care admissions. Despite rising case numbers, hospitalizations and deaths remain comparatively low, with many hospital admissions now incidental rather than driven by COVID-19 illness itself, underscoring a decoupling of infection rates from severe outcomes.

The immunity landscape in the UK reflects a complex interplay between natural infection and vaccination, with over 95% of adults possessing antibodies against SARS-CoV-2 by June 2026, largely due to widespread exposure and vaccination efforts where over 40% of adults have received three doses. However, vaccine-induced protection against reinfection wanes rapidly after about 75 days post-third dose, with reinfection risk increasing by over 220% beyond this period, though a fourth dose can modestly reduce this risk. Meanwhile, natural immunity from prior infections, including earlier variants and Omicron subvariants, confers substantial protection—ranging from approximately 56% to 84% efficacy against BA.5 reinfection—highlighting the enduring role of natural immunity in the endemic phase.

Reinfection dynamics have evolved notably with the dominance of the BA.5 Omicron subvariant, which by mid-2026 has supplanted earlier strains in the UK and US amid declining viral prevalence. Reinfection rates during the Omicron wave surged to 14.6%, a stark contrast to the 1–2% rates seen in Alpha and Delta waves, yet recent data shows reinfection risk has decreased from early Omicron levels—dropping from tenfold to about four or fivefold higher risk—signaling growing population immunity. This trend, coupled with BA.5's immense transmissibility, fuels optimism that it may represent the last significant variant, marking a pivotal moment in the shift toward endemicity.

Despite the encouraging trends toward endemicity and immunity buildup, COVID-19 continues to pose a mortality risk, with the UK reporting 825 deaths within 28 days of a positive test in a recent week of 2026. While the overall mortality rate is much lower than earlier in the pandemic and is slowly declining, this persistent death toll underscores the ongoing need for vigilance and adaptive public health strategies as the virus settles into its new phase.

By mid-2026, Omicron subvariants BA.4 and BA.5 have established dominance in regions like the UK and US, accounting for over 84% of cases, yet reassuringly they do not cause more severe disease or higher hospitalization rates compared to earlier BA.2 infections. This trend towards less severe outcomes is supported by UK data showing no increased hospital admission risk for BA.4 or BA.5, and a notable decline in COVID-related hospitalizations and ICU admissions in both the UK and US, signaling a shift toward endemicity.

Emerging Omicron subvariants such as BA.4.6 and BA.2.75 are gaining traction globally, with BA.4.6 progressively displacing BA.5 in the United States and being detected across multiple countries including Canada, Denmark, France, Australia, Germany, and Chile. BA.2.75, though currently a smaller fraction of cases, is growing rapidly at a 61% weekly rate in the US and is predicted to become more predominant, highlighting ongoing viral evolution and the need for vigilant surveillance.

BA.4.6 exhibits a modest growth advantage over BA.5 and demonstrates some immune escape capabilities, even among triple-dosed Pfizer vaccine recipients, suggesting it can partially evade antibodies elicited by prior BA.4 or BA.5 infections. Despite this, the overall risk of severe disease remains unchanged, underscoring a complex interplay between transmissibility, immune evasion, and clinical severity as the virus continues to adapt.

Prior infections with SARS-CoV-2 variants confer varying degrees of protection against BA.5, with the highest immunity observed following recent infections with closely related Omicron subvariants BA.1 and BA.2, offering approximately 77% protection. This immunological advantage likely contributes to the observed decrease in reinfection risk—from tenfold higher during early Omicron waves to about four to five times currently—reflecting a maturing population immunity landscape that tempers the impact of emerging variants.

By mid-2026, robust Portuguese data published in the New England Journal of Medicine revealed that natural immunity from prior Omicron BA1 or BA2 infections confers substantial protection—approximately 76.8%—against the BA5 variant, outperforming immunity from earlier strains like Wuhan (55.7%) and Delta (64.5%). This durability of natural immunity, with even the original 2020 Wuhan strain still offering over 55% protection against BA5 infection two years later, underscores the significant role of prior infection in shaping population-level resistance to emerging variants.

Despite compelling physiological evidence supporting the efficacy of natural immunity, countries including the UK, US, Canada, Australia, and New Zealand have exhibited a notable reluctance to openly acknowledge its protective value, reflecting a disconnect between scientific findings and public health messaging. This hesitancy persists even as experts caution against relying solely on antibody levels to gauge immunity, emphasizing that T memory cell responses—critical to long-term protection—are not predicted by circulating antibodies alone.

The debate over natural versus vaccine-induced immunity has become deeply politicized in the United States, where right-wing factions champion recognition of natural immunity while left-wing groups advocate universal vaccination. The US Centers for Disease Control and Prevention (CDC) maintains a policy recommending full vaccination regardless of prior infection, arguing that vaccine-induced immunity is more predictable. However, some experts challenge the FDA and CDC’s claims that vaccine immunity is categorically superior, suggesting that this assertion may not be fully supported by the evolving evidence.

Scientific studies indicate that immune memory following COVID-19 infection is robust, with approximately 95% of subjects retaining immunity at six months post-infection, though the longevity beyond this period remains uncertain. This highlights the complexity of immunity assessment, where both natural and vaccine-induced responses contribute to protection, but definitive conclusions about duration and comparative efficacy continue to evolve as new data emerge.

By mid-2026, vaccination strategies have increasingly emphasized tailored approaches for vulnerable populations, reflecting nuanced safety considerations and clinical guidance. The UK Health Security Agency updated vaccine timing for 12-17 year olds to mitigate myocarditis risk, underscoring the importance of clinical vigilance and nutritional support during recovery, while new guidance for pregnant women highlighted their elevated hospitalization risk and the need for informed maternity care mentorship. These targeted recommendations illustrate a shift from broad vaccination mandates toward personalized risk management in specific groups.

The UK Joint Committee on Vaccination and Immunisation (JCVI) pivoted its booster policy in autumn 2022 to focus on high-risk groups rather than universal campaigns, prioritizing residents and staff of care homes, frontline healthcare and social care workers, adults aged 50 and above, and clinically vulnerable individuals aged 5 to 49. This strategy acknowledges the limited evidence that vaccines prevent transmission in a highly vaccinated population amid widespread natural immunity, marking a transition from emergency pandemic response to recovery and optimized protection against severe COVID-19 outcomes during winter surges.

The approval and deployment of Moderna’s Spikevax bivalent Original/Omicron booster in the UK represents a significant advancement in vaccine technology, combining 25 micrograms each targeting the original SARS-CoV-2 strain and Omicron BA.1 variant. Clinical data demonstrated an approximately eightfold increase in neutralizing antibody titers against Omicron in baseline seronegative individuals, with a safety profile comparable to the original mRNA-1273 vaccine. This bivalent booster is central to updated booster campaigns, offering enhanced immunity against evolving variants without introducing new safety concerns.

Safety monitoring continues to inform vaccination policies, as evidenced by a population-based cohort study in Ontario identifying higher myocarditis and pericarditis rates following mRNA-1273 vaccination compared to BNT162b2, particularly among males aged 18 to 24. These product-specific safety signals have influenced nuanced recommendations, balancing booster benefits with risk mitigation in younger populations, and reinforcing the importance of ongoing pharmacovigilance in adapting COVID-19 vaccination strategies.

By mid-2026, the United Kingdom and Gibraltar exemplify a notable epidemiological pattern where COVID-19 cases are rising yet hospitalizations and deaths are declining, reflecting a decoupling of infection rates from severe outcomes. This trend is underpinned by widespread immunity, with over 90% of UK adults possessing antibodies and approximately 98% having been exposed to SARS-CoV-2 through infection or vaccination, including more than 40% having received three vaccine doses. As one analysis highlights, the UK's success in managing hospitalizations is attributed not to a less pathogenic Omicron variant but to this robust immunity landscape.

Contrasting epidemiological trajectories emerge globally as autumn 2026 unfolds: the United States and Canada report declining COVID-19 cases and effective reproduction numbers (R) below 1, signaling waning transmission, while parts of Europe such as the Netherlands and Ireland experience sharp case surges with R values above 1. Despite improving hospitalization trends in the US, hospitalization rates per capita remain higher than in the UK and other nations, and COVID-19 deaths persist at stubbornly high levels, underscoring ongoing serious impacts amid lower vaccination coverage compared to countries like Australia and New Zealand.

Divergences in vaccine deployment and natural infection histories contribute to differing COVID-19 dynamics between countries, particularly between the US and UK. The UK’s extensive use of the Oxford AstraZeneca vaccine contrasts with the US preference for Pfizer, Moderna, and Johnson & Johnson vaccines, while the US may have accrued more community herd immunity through natural infections. These factors, alongside varying levels of population immunity, likely influence the US’s current significant decline in new daily cases versus the UK’s ongoing surge, though the precise drivers remain uncertain.

Recent data from July 2026 indicate a continued decline in COVID-19 hospitalizations in both the UK and US, with the UK seeing ICU admissions remain low throughout the Omicron period and only about 40% of hospitalized patients primarily admitted for COVID-19, reflecting a high incidence of incidental findings. Regional variations within the UK, such as London’s earlier and higher case surges, suggest that other areas may soon follow similar downward trends. Meanwhile, the US shows a 16% reduction in cases and 8% decrease in hospitalizations, trailing the UK by one to two weeks, although test positivity remains relatively high at around 15%, signaling persistent viral circulation dominated by Omicron subvariants BA.5 and BA.4.